Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate to severe atopic dermatitis: including adverse events of special interest. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 7, n. 2, p. s143, 2023. DOI: 10.25251/skin.7.supp.143. Disponível em: https://skin.dermsquared.com/skin/article/view/2027. Acesso em: 17 may. 2025.